Brokers Set Expectations for Krystal Biotech FY2025 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Krystal Biotech in a note issued to investors on Thursday, February 20th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of $6.22 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $215.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the previous year, the company posted $0.30 earnings per share. The company’s revenue was up 116.4% compared to the same quarter last year.

Several other research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Wednesday, February 19th. Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Trading Down 3.1 %

Shares of NASDAQ KRYS opened at $181.10 on Monday. The company has a 50 day simple moving average of $158.24 and a two-hundred day simple moving average of $175.31. The stock has a market cap of $5.22 billion, a price-to-earnings ratio of 60.57 and a beta of 0.84. Krystal Biotech has a 12 month low of $125.85 and a 12 month high of $219.34.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently modified their holdings of the business. Entropy Technologies LP acquired a new position in Krystal Biotech in the 4th quarter worth about $548,000. Summit Trail Advisors LLC purchased a new stake in shares of Krystal Biotech in the third quarter valued at approximately $1,893,000. Swiss National Bank raised its stake in shares of Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after buying an additional 2,900 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after buying an additional 15,545 shares in the last quarter. Finally, Citigroup Inc. grew its stake in Krystal Biotech by 65.4% in the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).